CME Group Inc. (CME) operating KPIs
CMENasdaqSecurity & Commodity Brokers, Dealers, Exchanges & ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 23, 2026Score 9/3021% above fair value
$303.14+6.72 (+2.27%)
Close on Oct 30, 2026Market cap $109.00BP/E 25.7Yield 1.65%
CME indefinite-lived trading products intangible assets (CBOT, NYMEX, COMEX & NEX licenses) ($M)
Form 10-K Note 6 Intangible Assets and Goodwill & SEC XBRL
Latest, Q3 2026
2,440
Period ended Sep 30, 2026
Change on a year earlier
-8.5%
2,668 in Q3 2025
History
43 quarters
Since Q1 2016
Sources
42
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Indefinite-lived trading products intangible assets (CBOT, NYMEX, COMEX & NEX licenses) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 2,440 | -8.5% | CME Form 10-Q (2026-10-23) ↗ |
| Q2 2026 | Jun 30, 2026 | 2,495 | -8.6% | CME Form 10-Q (2026-07-24) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,551 | -8.0% | CME Form 10-Q (2026-04-24) ↗ |
| Q4 2025 | Dec 31, 2025 | 2,611 | -84.8% | CME Form 10-Q (2026-10-23) ↗ |
| Q3 2025 | Sep 30, 2025 | 2,668 | -7.8% | CME Form 10-Q (2025-10-24) ↗ |
| Q2 2025 | Jun 30, 2025 | 2,729 | -7.0% | CME Form 10-Q (2025-07-25) ↗ |
| Q1 2025 | Mar 31, 2025 | 2,773 | -7.3% | CME Form 10-Q (2025-04-30) ↗ |
| Q4 2024 | Dec 31, 2024 | 17,175 | 0.0% | CME Form 10-K (2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 2,892 | -6.6% | CME Form 10-Q (2024-11-08) ↗ |
| Q2 2024 | Jun 30, 2024 | 2,933 | -7.2% | CME Form 10-Q (2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 2,990 | -7.1% | CME Form 10-Q (2024-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 17,175 | 0.0% | CME Form 10-K (2025-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 3,095 | -6.3% | CME Form 10-Q (2023-11-01) ↗ |
| Q2 2023 | Jun 30, 2023 | 3,160 | -6.6% | CME Form 10-Q (2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 3,217 | -7.1% | CME Form 10-Q (2023-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 17,175 | 0.0% | CME Form 10-K (2024-02-28) ↗ |
| Q3 2022 | Sep 30, 2022 | 3,302 | -8.1% | CME Form 10-Q (2022-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 3,382 | -7.6% | CME Form 10-Q (2022-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 3,463 | -6.8% | CME Form 10-Q (2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 17,175 | 0.0% | CME Form 10-K (2023-02-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 3,593 | -26.6% | CME Form 10-Q (2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 3,659 | -25.8% | CME Form 10-Q (2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 3,717 | -25.6% | CME Form 10-Q (2021-05-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 17,175 | 0.0% | CME Form 10-K (2022-02-25) ↗ |
| Q3 2020 | Sep 30, 2020 | 4,894 | -71.5% | CME Form 10-Q (2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 4,932 | -71.3% | CME Form 10-Q (2020-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 4,998 | -70.9% | CME Form 10-Q (2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 17,175 | 0.0% | CME Form 10-K (2021-02-26) ↗ |
| Q3 2019 | Sep 30, 2019 | 17,175 | 0.0% | CME Form 10-Q (2019-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 17,175 | 0.0% | CME Form 10-Q (2019-08-07) ↗ |
| Q1 2019 | Mar 31, 2019 | 17,175 | 0.0% | CME Form 10-Q (2019-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 17,175 | 0.0% | CME Form 10-K (2020-02-28) ↗ |
| Q3 2018 | Sep 30, 2018 | 17,175 | 0.0% | CME Form 10-Q (2018-11-02) ↗ |
| Q2 2018 | Jun 30, 2018 | 17,175 | 0.0% | CME Form 10-Q (2018-08-01) ↗ |
| Q1 2018 | Mar 31, 2018 | 17,175 | 0.0% | CME Form 10-Q (2018-05-03) ↗ |
| Q4 2017 | Dec 31, 2017 | 17,175 | 0.0% | CME Form 10-K (2019-02-28) ↗ |
| Q3 2017 | Sep 30, 2017 | 17,175 | 0.0% | CME Form 10-Q (2017-11-02) ↗ |
| Q2 2017 | Jun 30, 2017 | 17,175 | 0.0% | CME Form 10-Q (2017-08-02) ↗ |
| Q1 2017 | Mar 31, 2017 | 17,175 | 0.0% | CME Form 10-Q (2017-05-04) ↗ |
| Q4 2016 | Dec 31, 2016 | 17,175 | – | CME Form 10-K (2018-03-01) ↗ |
| Q3 2016 | Sep 30, 2016 | 17,175 | – | CME Form 10-Q (2016-11-04) ↗ |
| Q2 2016 | Jun 30, 2016 | 17,175 | – | CME Form 10-Q (2016-08-04) ↗ |
| Q1 2016 | Mar 31, 2016 | 17,175 | – | CME Form 10-Q (2016-05-04) ↗ |
Breakdown
What makes up indefinite-lived trading products intangible assets (cbot, nymex, comex & nex licenses)
- Indefinite-lived trade names–
- Total amortizable intangible assets, net1,990 · Q3 2026
- Clearing firm, market data & customer relationships, gross–
- Finite-lived intangible amortization schedule — Year 1221 · Q3 2026
- Finite-lived intangible amortization schedule — Year 2215 · Q3 2026
- Finite-lived intangible amortization schedule — Year 3215 · Q3 2026
- Finite-lived intangible amortization schedule — Year 4215 · Q3 2026
- Finite-lived intangible amortization schedule — Year 5215 · Q3 2026
Cite this data
StockData. (2026). CME Indefinite-lived trading products intangible assets (CBOT, NYMEX, COMEX & NEX licenses) ($M), quarterly Q1 2016–Q3 2026 [Data set]. Compiled from CME SEC filings and investor materials. https://stockdatahq.com/stocks/cme/kpis/intang-trading-products
See every metric in the CME KPI table. Data updated Oct 28, 2026.